Revealing the therapeutic potential of dupilumab: a case report on managing post-COVID-19 chronic pruritus in a geriatric patient

This case report describes a 73-year-old Caucasian male who contracted COVID-19 and struggled with chronic, severe pruritus after that. The patient's pruritus resisted numerous conventional and unconventional therapy modalities, highlighting the difficulty of treating post-COVID-19 dermatological symptoms. Pruritus in the patient was significantly alleviated due to therapy with Dupixent, a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. Treatment of the condition improved significantly with the use of Dupixent. The report describes the story of the patient's journey, from the first-time symptoms showed up after COVID-19 infection, through several treatments that was not effective, to when the patient's symptoms disappeared after starting Dupixent. The patient's recent SARS-CoV-2 infection may be connected to the immune-mediated process shown by the patient's histopathological results. Even though these results are based on a single instance, they highlight COVID-19's ability to cause chronic pruritus and recommend Dupixent as a possible treatment approach. More study is required to confirm these findings and investigate possible immunological connections between COVID-19 and chronic pruritus.